Table 3.
Performance of Proclarix, PSAD, and the ERSPC MRI predictive model for csPCa detection in men in the PI-RADS 3 category using the most sensitive thresholds
| Parameter | csPCs detection, n/N (%) |
||
|---|---|---|---|
| Proclarix (cutoff = 10%) | PSAD (cutoff = 0.07 ng/ml/cm3) | ERSPC MRI RC (cutoff = 1.5%) | |
| Sensitivity | 25/25 (100) | 21/25 (84.0) | 24/25 (96.0) |
| Specificity | 36/144 (25.0) | 41/144 (28.5) | 11/144 (7.6) |
| Negative predictive value | 36/36 (100) | 41/45 (91.1) | 11/12 (91.7) |
| Positive predictive value | 25/133 (19.8) | 21/124 (16.0) | 24/157 (15.3) |
| Accuracy | 61/169 (36.1) | 62/169 (36.7) | 35/169 (20.7) |
| Prostate biopsies avoided | 36/169 (21.3) | 45/169 (26.2) | 12/169 (7.1) |
| Decrease in iPCa overdetection | 9/169 (5.3) | 9/169 (5.3) | 2/169 (1.2) |
| Misdiagnosis of csPCa | 0/25 (0) | 4/25 (16.0) | 1/25 (4.0) |
PI-RADS = Prostate Imaging-Reporting and Data System; PCa = prostate cancer; iPCa = insignificant PCa; csPCa = clinically significant PCa; PSAD =prostate-specific antigen density; ERSPC = European Randomized Study of Screening for Prostate Cancer; MRI = magnetic resonance imaging; RC = risk calculator.